Serica Energy reported a delay in production at its Triton floating vessel due to extended maintenance, pushing output resumption to late November. Despite this, the company maintained its 2026 cash flow forecast of $450-$475 million, supported by strong gas prices and recent asset acquisitions. Production averaged 37,100 boepd in the first nine months, up 44% year-on-year, though Q3 output dropped due to maintenance. Serica plans a multi-well drilling campaign starting in 2027 and aims to move to the London Stock Exchange Main Market, potentially joining the FTSE 250 index in December.
Serica Energy's update on its Triton production delay provides context for energy sector investors. For readers following energy stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: out of 79 priced US energy stocks, 38 rose and 37 fell. Notable movers include Ovintiv Inc. (OVV) at USD 69.24 with a +3.73% change and Canadian Natural Resources Ltd. (CNQ) at USD 53.75 with a +3.72% change.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
